{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T20:37:33Z","timestamp":1781037453048,"version":"3.54.1"},"reference-count":24,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2018,5,21]],"date-time":"2018-05-21T00:00:00Z","timestamp":1526860800000},"content-version":"vor","delay-in-days":20,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["headachejournal.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Headache"],"published-print":{"date-parts":[[2018,5]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To determine the potential impact of erenumab, a human anti\u2010calcitonin gene\u2010related peptide (CGRP) receptor monoclonal antibody, on total exercise time (TET), time to exercise\u2010induced angina, and ST depression in a double\u2010blind, placebo\u2010controlled study in patients with stable angina due to documented coronary artery disease.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The relative importance of the CGRP receptor pathway during myocardial ischemia has not been established.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>An exercise treadmill test was conducted following a single IV infusion of erenumab 140 mg or placebo. The primary endpoint was the change from baseline in exercise duration as measured by TET with a noninferiority margin of \u221290 seconds. Safety follow\u2010up visits occurred through week 12. Eighty\u2010eight participants were included in the analysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      LS mean (SE) change in TET was \u22122.9 [14.8] seconds in the erenumab group and 8.1 [14.4] seconds in placebo; adjusted mean (90% CI) treatment difference was \u221211.0 (\u201344.9, 22.9) seconds. The CI lower bound (\u201344.9 sec) did not reach pre\u2010defined non\u2010inferiority margin of \u221290 seconds, demonstrating that TET change from baseline in the erenumab group was non\u2010inferior to placebo. There was no difference in time to exercise\u2010induced angina in erenumab and placebo groups (median [90% CI] time of 500 [420, 540] vs 508 [405, 572] seconds; hazard ratio [90% CI]: 1.11 [0.73, 1.69],\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u2009.69) or time to onset of \u22651 mm ST\u2010segment depression (median [90% CI] time of 407 [380, 443] vs 420 [409,480] seconds; hazard ratio [95% CI]: 1.14 [0.76, 1.69],\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u2009.59). Adverse events were reported by 27% and 32% of patients in erenumab and placebo groups.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Erenumab did not adversely affect exercise time in a high cardiovascular risk population of patients, supporting that inhibition of the canonical CGRP receptor does not worsen myocardial ischemia.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/head.13316","type":"journal-article","created":{"date-parts":[[2018,5,31]],"date-time":"2018-05-31T19:53:10Z","timestamp":1527796390000},"page":"715-723","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":117,"title":["A Randomized, Double\u2010Blind, Placebo\u2010Controlled Study to Evaluate the Effect of Erenumab on Exercise Time During a Treadmill Test in Patients With Stable Angina"],"prefix":"10.1111","volume":"58","author":[{"given":"Christophe","family":"Depre","sequence":"first","affiliation":[{"name":"Amgen Inc. Thousand Oaks CA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lubomir","family":"Antalik","sequence":"additional","affiliation":[{"name":"Cardiological Department Regional Hospital Slovakia (L. Antalik)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amaal","family":"Starling","sequence":"additional","affiliation":[{"name":"Mayo Clinic Scottsdale AZ USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Koren","sequence":"additional","affiliation":[{"name":"Jacksonville Center for Clinical Research Jacksonville FL USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Osaro","family":"Eisele","sequence":"additional","affiliation":[{"name":"Amgen Inc. Thousand Oaks CA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert A.","family":"Lenz","sequence":"additional","affiliation":[{"name":"Amgen Inc. Thousand Oaks CA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel D.","family":"Mikol","sequence":"additional","affiliation":[{"name":"Amgen Inc. Thousand Oaks CA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2018,5,21]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1177\/0333102409355601"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1992.03480010072027"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/head.12482"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1159\/000028339"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1093\/cvr\/27.8.1477"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/0140-6736(90)90040-C"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5381.2011.01717.x"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0165-6147(00)01555-8"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0167-0115(99)00039-7"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2005.12.039"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.108.144220"},{"key":"e_1_2_9_13_1","first-page":"588","article-title":"Effects of calcitonin gene\u2010related peptide and BIBN4096BS on myocardial ischemia in anesthetized rats","volume":"22","author":"Wu DM","year":"2001","journal-title":"Acta Pharmacol Sin."},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.89.1.366"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2011.246"},{"key":"e_1_2_9_16_1","first-page":"1","article-title":"Effects of AMG 334 on human isolated coronary artery [abstract]","volume":"36","author":"Rubio\u2010Beltr\u00e1n E","year":"2016","journal-title":"Cephalalgia."},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI102207"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI102208"},{"key":"e_1_2_9_19_1","unstructured":"GouxS et al. MedDRA Maintenance and Support Services Organization Annual Report 2014;2014."},{"key":"e_1_2_9_20_1","unstructured":"U.S Department of Health and Human Services NIoH N.C.I. Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0;2010."},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2005.02479.x"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(17)30083-2"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(16)00019-3"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11095-017-2183-6"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2017-316074.62"}],"container-title":["Headache: The Journal of Head and Face Pain"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fhead.13316","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/head.13316","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/head.13316","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/headachejournal.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/head.13316","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T12:07:15Z","timestamp":1762085235000},"score":1,"resource":{"primary":{"URL":"https:\/\/headachejournal.onlinelibrary.wiley.com\/doi\/10.1111\/head.13316"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5]]},"references-count":24,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2018,5]]}},"alternative-id":["10.1111\/head.13316"],"URL":"https:\/\/doi.org\/10.1111\/head.13316","archive":["Portico"],"relation":{},"ISSN":["0017-8748","1526-4610"],"issn-type":[{"value":"0017-8748","type":"print"},{"value":"1526-4610","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,5]]},"assertion":[{"value":"2017-12-20","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-03-09","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-05-21","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}